KURA
Kura Oncology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+3/100
Last price
10.53
▼ 0.09 (0.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.62
Prev close
10.62
Day high
10.88
Day low
10.34
Volume
1.30M
Market cap
$936.76M
P/E (TTM)
—
52W range
7.36 – 13.90
Day trading desk
Gap from prior close
+0.00%
Prior close 10.62
VWAP
10.58
-0.45% from price
Relative volume
0.58×
Quiet session
Session range
15.09%
10.34 – 11.90
Position in range
12%
Near session low
ATR (14D)
0.50
4.71% of price
Prior day high
10.80
PDH
Prior day low
10.29
PDL
Bid / ask spread
—
Quote not published
Session volume
1.03M
Avg 1.79M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.55%
-4.5%
1M
-20.53%
-21.7%
3M
-13.12%
-17.6%
6M
+19.39%
+1.2%
YTD
+1.35%
-12.9%
1Y
+10.03%
-6.4%
3Y
+15.46%
-66.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KURA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-32.94K
Net selling
Buy transactions
2
200.00K shares
Sell transactions
12
232.94K shares
Net transactions
+14
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
1.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | FORD KATHLEEN Chief Operating Officer |
SELL | 10.57K | $111.93K | Direct |
| Sep 29, 26 | POWL BRIAN T Officer |
SELL | 32.45K | $345.04K | Direct |
| Sep 29, 26 | LEONI MOLLIE M.D. Officer |
SELL | 41.25K | $440.24K | Direct |
| Sep 28, 26 | BAIR TERESA BROPHY Officer |
SELL | 8.44K | $88.62K | Direct |
| Sep 28, 26 | DOYLE THOMAS JAMES Officer |
SELL | 4.61K | $48.36K | Direct |
| Aug 24, 26 | WILSON TROY EDWARD Chief Executive Officer |
BUY | 100.00K | $1.24M | Indirect |
| Aug 21, 26 | POWL BRIAN T Officer |
SELL | 4.34K | $51.66K | Direct |
| Aug 19, 26 | BAIR TERESA BROPHY Officer |
SELL | 31.49K | $397.68K | Direct |
| Aug 17, 26 | WILSON TROY EDWARD Chief Executive Officer |
BUY | 100.00K | $1.11M | Indirect |
| Jun 18, 26 | LEONI MOLLIE M.D. Officer |
SELL | 84.93K | $834.28K | Direct |
| May 21, 26 | POWL BRIAN T Officer |
SELL | 10.00K | $110.00K | Direct |
| May 19, 26 | FORD KATHLEEN Chief Operating Officer |
SELL | 2.26K | $20.48K | Direct |
| May 19, 26 | POWL BRIAN T Officer |
SELL | 339 | $3.12K | Direct |
| May 18, 26 | BAIR TERESA BROPHY Officer |
SELL | 2.26K | $21.16K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAIR TERESA BROPHY |
Officer | 187.00K | Sale |
BURROWS FRANCIS J. PH.D. |
Officer | 32.42K | Sale |
DOYLE THOMAS JAMES |
Officer | 142.93K | Sale |
FORD KATHLEEN |
Chief Operating Officer | 142.99K | Sale |
HASNAIN FAHEEM |
Director | 23.98K | Sale |
LEONI MOLLIE M.D. |
Officer | 141.09K | Sale |
MALLEY THOMAS ROBERT |
Director | 149.56K | Conversion of Exercise of derivative security |
POWL BRIAN T |
Officer | 136.82K | Sale |
WILSON TROY EDWARD |
Chief Executive Officer | — | Purchase |
Fundamentals
Market cap$936.76M
Enterprise value$442.19M
Revenue (TTM)$77.22M
Gross profit$-182.81M
EBITDA$-316.80M
Net income$-296.78M
EPS (TTM)$-3.37
Free cash flow$-165.88M
Total cash$519.02M
Total debt$24.45M
Book value / share$0.54
Shares outstanding88.96M
Float70.53M
Short % of float17.10%
Dividend yield0.00%
Beta (5Y)0.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.48
PEG ratio—
Price / sales—
Price / book19.36
EV / revenue5.73
EV / EBITDA-1.40
Gross margin-236.72%
Operating margin-349.77%
Profit margin0.00%
Return on equity-167.71%
Return on assets-31.30%
Debt / equity50.50
Current ratio4.73
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $67.48M | $53.88M | $0 | $0 | +25.2% |
| Operating revenue | $67.48M | $53.88M | $0 | $0 | +25.2% |
| Cost of revenue | $57.00K | $0 | $0 | — | — |
| Gross profit | $67.42M | $53.88M | $0 | — | +25.1% |
| Research & development | $251.07M | $169.97M | $115.23M | $92.81M | +47.7% |
| Selling, general & admin | $119.98M | $77.11M | $50.57M | $47.05M | +55.6% |
| Total operating expense | $371.06M | $247.08M | $165.80M | $139.87M | +50.2% |
| Operating income | -$303.63M | -$193.19M | -$165.80M | -$139.87M | -57.2% |
| Net interest income | $25.26M | $21.23M | $13.17M | $4.03M | +19.0% |
| Pre-tax income | -$278.37M | -$171.97M | -$152.63M | -$135.84M | -61.9% |
| Tax provision | $297.00K | $2.02M | $0 | $0 | -85.3% |
| Net income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -60.2% |
| Net income to common | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -60.2% |
| Basic EPS | -3.18 | -2.02 | -2.08 | -2.03 | -57.4% |
| Diluted EPS | -3.18 | -2.02 | -2.08 | -2.03 | -57.4% |
| EBIT | -$276.86M | -$170.35M | -$151.08M | -$135.61M | -62.5% |
| EBITDA | -$275.82M | -$169.50M | -$150.23M | -$134.85M | -62.7% |
| Basic shares | 87.68M | 86.16M | 73.23M | 66.99M | +1.8% |
| Diluted shares | 87.68M | 86.16M | 73.23M | 66.99M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $149.10M | $224.46M | $37.32M | $51.80M | -33.6% |
| Cash & short-term investments | $667.24M | $727.39M | $423.96M | $437.99M | -8.3% |
| Accounts receivable | $8.80M | $2.06M | — | — | +327.4% |
| Inventory | $413.00K | $0 | — | — | — |
| Total current assets | $708.66M | $744.83M | $432.48M | $446.43M | -4.9% |
| Property, plant & equipment | $15.16M | $7.49M | $8.85M | $6.38M | +102.5% |
| Total assets | $738.36M | $760.16M | $448.94M | $456.31M | -2.9% |
| Total current liabilities | $116.97M | $78.71M | $35.26M | $24.06M | +48.6% |
| Current debt | — | $2.61M | — | — | — |
| Long-term debt | $9.71M | $6.92M | $9.33M | $9.16M | +40.4% |
| Total debt | $20.46M | $16.59M | $17.20M | $14.02M | +23.3% |
| Total liabilities | $564.23M | $346.52M | $51.66M | $36.03M | +62.8% |
| Retained earnings | -$1.17B | -$895.42M | -$721.44M | -$568.81M | -31.1% |
| Shareholder equity | $174.13M | $413.64M | $397.27M | $420.28M | -57.9% |
| Working capital | $591.69M | $666.12M | $397.22M | $422.37M | -11.2% |
| Net tangible assets | $174.13M | $413.64M | $397.27M | $420.28M | -57.9% |
| Shares issued | 87.86M | 78.23M | 74.35M | 68.31M | +12.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -60.2% |
| Depreciation & amortisation | $1.03M | $848.00K | $849.00K | $759.00K | +21.7% |
| Stock-based compensation | $37.11M | $33.90M | $28.08M | $26.32M | +9.5% |
| Change in working capital | $184.44M | $286.17M | $7.82M | -$2.98M | -35.5% |
| Operating cash flow | -$64.06M | $134.32M | -$124.82M | -$110.06M | -147.7% |
| Capital expenditure | -$6.64M | -$472.00K | -$168.00K | -$626.00K | -1,306.4% |
| Investing cash flow | -$13.10M | -$101.59M | $15.56M | $32.63M | +87.1% |
| Financing cash flow | $1.79M | $154.42M | $94.78M | $38.56M | -98.8% |
| Free cash flow | -$70.70M | $133.84M | -$124.99M | -$110.69M | -152.8% |
| End cash position | $149.10M | $224.46M | $37.32M | $51.80M | -33.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $20.87M | $18.27M | $17.34M | $20.75M | $15.29M | — | +14.3% |
| Operating revenue | $20.87M | $18.27M | $17.34M | $20.75M | $15.29M | — | +14.3% |
| Cost of revenue | $243.00K | $262.00K | — | — | $0 | $0 | -7.3% |
| Gross profit | $20.63M | $18.00M | — | — | $15.29M | $14.11M | +14.6% |
| Research & development | $61.89M | $65.26M | $64.41M | $67.91M | $62.78M | — | -5.2% |
| Selling, general & admin | $31.75M | $31.55M | $39.14M | $32.84M | $25.17M | — | +0.6% |
| Total operating expense | $93.64M | $96.82M | $103.55M | $100.75M | $87.95M | — | -3.3% |
| Operating income | -$73.01M | -$78.81M | -$86.27M | -$80.00M | -$72.67M | — | +7.4% |
| Net interest income | $4.69M | $5.49M | $5.34M | $5.88M | $6.54M | — | -14.6% |
| Pre-tax income | -$68.32M | -$73.33M | -$80.93M | -$74.12M | -$66.12M | — | +6.8% |
| Tax provision | $5.00K | $8.00K | $71.00K | $0 | $0 | — | -37.5% |
| Net income | -$68.33M | -$73.33M | -$81.00M | -$74.12M | -$66.12M | — | +6.8% |
| Net income to common | -$68.33M | -$73.33M | -$81.00M | -$74.12M | -$66.12M | — | +6.8% |
| Basic EPS | -0.77 | -0.83 | -0.92 | -0.85 | -0.75 | — | +7.2% |
| Diluted EPS | -0.77 | -0.83 | -0.92 | -0.85 | -0.75 | — | +7.2% |
| EBIT | -$67.98M | -$72.99M | -$80.58M | -$73.72M | -$65.73M | — | +6.9% |
| EBITDA | -$67.61M | -$72.63M | -$80.18M | -$73.56M | -$65.51M | — | +6.9% |
| Basic shares | 88.86M | 88.61M | 88.05M | 87.64M | 87.59M | — | +0.3% |
| Diluted shares | 88.86M | 88.61M | 88.05M | 87.64M | 87.59M | — | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $70.24M | $39.08M | $149.10M | $95.29M | $81.95M | — | +79.7% |
| Cash & short-term investments | $519.02M | $580.82M | $667.24M | $549.66M | $630.73M | — | -10.6% |
| Accounts receivable | $9.45M | $9.35M | $8.80M | — | — | — | +1.0% |
| Inventory | $2.48M | $843.00K | $413.00K | — | — | — | +194.8% |
| Total current assets | $559.44M | $623.78M | $708.66M | $620.66M | $660.08M | — | -10.3% |
| Property, plant & equipment | $14.62M | $14.78M | $15.16M | $14.94M | $11.78M | — | -1.0% |
| Total assets | $587.79M | $652.55M | $738.36M | $649.38M | $682.42M | — | -9.9% |
| Total current liabilities | $118.19M | $101.50M | $116.97M | $121.30M | $107.17M | — | +16.5% |
| Current debt | $4.22M | — | — | $4.34M | $3.11M | $1.92M | — |
| Long-term debt | $5.57M | $9.75M | $9.71M | $5.34M | $6.51M | — | -42.8% |
| Total debt | $24.45M | $24.27M | $20.46M | $19.47M | $19.47M | — | +0.7% |
| Total liabilities | $539.36M | $544.67M | $564.23M | $406.84M | $376.94M | — | -1.0% |
| Retained earnings | -$1.32B | -$1.25B | -$1.17B | -$1.09B | -$1.02B | — | -5.5% |
| Shareholder equity | $48.43M | $107.88M | $174.13M | $242.54M | $305.49M | — | -55.1% |
| Working capital | $441.25M | $522.29M | $591.69M | $499.36M | $552.90M | — | -15.5% |
| Net tangible assets | $48.43M | $107.88M | $174.13M | $242.54M | $305.49M | — | -55.1% |
| Shares issued | 88.95M | 88.76M | 87.86M | 87.02M | 86.80M | — | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$68.33M | -$73.33M | -$81.00M | -$74.12M | -$66.12M | +6.8% |
| Depreciation & amortisation | $369.00K | $355.00K | $403.00K | $164.00K | $224.00K | +3.9% |
| Stock-based compensation | $8.21M | $8.42M | $11.35M | $10.96M | $6.95M | -2.5% |
| Change in working capital | -$2.17M | -$20.50M | $187.80M | -$15.86M | $32.55M | +89.4% |
| Operating cash flow | -$62.55M | -$85.85M | $117.27M | -$80.63M | -$28.78M | +27.1% |
| Capital expenditure | -$656.00K | -$128.00K | -$2.32M | -$2.57M | -$1.46M | -412.5% |
| Investing cash flow | $92.21M | -$24.23M | -$64.60M | $93.97M | $58.94M | +480.5% |
| Financing cash flow | $1.50M | $69.00K | $1.14M | $0 | $515.00K | +2,072.5% |
| Free cash flow | -$63.20M | -$85.98M | $114.95M | -$83.19M | -$30.23M | +26.5% |
| End cash position | $70.24M | $39.08M | $149.10M | $95.29M | $81.95M | +79.7% |
Options analytics
Put / call volume
2.03
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.00
-81.0% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
552
Contracts, this expiry
Put volume
1.12K
Contracts, this expiry
Heaviest call OI
2.00
2 contracts
Heaviest put OI
7.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.88 | -0.77 | +12.1% |
| Mar 2026 | -0.78 | — | — |
| Dec 2025 | -0.49 | -0.92 | -88.6% |
| Sep 2025 | -0.68 | -0.85 | -25.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.81 | 10 | $23.81M | +14.8% |
| Next quarter | -0.79 | 10 | $33.10M | +91.0% |
| Current year | -3.17 | 10 | $96.13M | +42.5% |
| Next year | -2.35 | 10 | $208.37M | +116.8% |
Analyst targets & ownership
Mean target$31.85
High target$76.00
Low target$15.00
Implied upside202.43%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy3 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders1.40%
Held by institutions100.08%
Institutions holding304
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.72
-1.80% from price
SMA 20
11.16
-5.61% from price
SMA 50
11.19
-5.86% from price
SMA 100
10.70
-1.58% from price
SMA 200
9.81
+7.36% from price
EMA 12
10.88
-3.24% from price
EMA 26
11.19
-5.90% from price
EMA 50
11.16
-5.68% from price
RSI (14)
37.6
Neutral
MACD (12,26,9)
-0.31
Hist -0.10
ATR (14)
0.50
4.71% of price
Realised vol 30D
46.7%
Annualised
Bollinger upper
12.11
20, 2σ
Bollinger lower
10.20
20, 2σ
50 / 200 cross
Golden
11.19 vs 9.81
Trend bias
Above 200
+7.36%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.39
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
46.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.0%
Peak to trough
Max drawdown 5Y
-76.5%
Peak to trough
ATR 14
0.50
4.71% of price
Beta (reported)
0.47
5Y monthly, from filing
Short interest
Shares short
14.82M
Prior 13.12M
Change vs prior
+12.9%
Shorts adding
% of float
17.10%
Elevated
% of shares out
16.66%
Against total outstanding
Days to cover
6.4
Crowded exit
Float
70.53M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | JP Morgan | INITIATED | — | Overweight |
| Aug 24, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 13, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 28, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jun 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 14, 26 | Lake Street | INITIATED | — | Buy |
| Mar 24, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 13, 26 | UBS | MAINTAINED | Buy | Buy |
| Mar 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jan 13, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jan 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 24, 25 | Barclays | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-29
Offering Registrations
S-8 · 2026-06-04
Proxy Statements
DEFA14A · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-05-12
Annual Report to Shareholders
ARS · 2026-04-10
Headlines
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
GlobeNewswire · 6d ago
JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target
MT Newswires · 6d ago
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
GlobeNewswire · 8d ago
Kura spins diabetes work into a Lilly-backed biotech startup
BioPharma Dive · 28d ago
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Benzinga · 28d ago
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding
MT Newswires · 28d ago
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
GlobeNewswire · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.